|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Gen-Probe signed a supply agreement with Roche Molecular Systems, Inc. under which Gen-Probe will purchase products for use in molecular diagnostic assays for human papillomavirus. Roche will manufacture APTIMA format DNA probes for HPV, which Gen-Probe will use to expand the menu for the TIGRIS system. GeneGo Inc. received a Phase I SBIR grant from the National Cancer Institute for elucidation and analysis of cellular networks implicated in breast cancer using GeneGo's MetaCore integrated systems biology platform for mining of high-throughput experimental data. GMP Companies, Inc. has developed Conversion Technology and Conversion Analysis Processes to identify hereditary mutations in people with a family history of colorectal cancer. Conversion Technology is based on discoveries by scientists at The Johns Hopkins Kimmel Cancer Center. A routine blood sample analyzed by the Conversion Analysis process separates the chromosomes and allows for more accurate analysis of potential abnormalities. Invitrogen Corp. announced it will buy Dynal Biotech, a specialist in molecular separation and purification. This is in addition to Invitrogen's acquisition of Zymed Laboratories in January 2005. QIAGEN GmbH entered into a manufacturing and supply agreement with Roche Molecular Systems who will market QIAGEN's media sample preparation kits under their AmpliLute trademark. This customized kit will incorporate a specific version of QIAGEN's QIAamp technology to purify DNA from specimens stored in liquid cytology media. SeraCare Life Sciences, Inc. is developing an Immuno-PCR test for infectious prions. The Immuno-PCR test will enable the detection of the Mad Cow protein in blood, cerebrospinal fluid, or nerve tissue by combining antigen capture and PCR into a two-stage Immuno-PCR testing regimen. SeraCare intends to commercialize the test by the end of 2005.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: March 7, 2005 |
![[Page Banner Image]](images/hmole.gif){kind=small}
